

Corporate integrity agreement

On June 30, 2020, Novartis Corporation entered into a Corporate Integrity Agreement (CIA) with the Office of the Inspector General (OIG) of the United States Department of Health and Human Services (HHS).

The new CIA is part of two recent settlements with the US Government. Novartis has agreed to a settlement of USD 678 million to resolve a civil suit that originated within the Southern District of New York regarding speaker programs conducted between 2002 and 2011. Novartis has also agreed to a settlement of USD 51.25 million to resolve an investigation in the District of Massachusetts concerning the company's support of certain independent charitable co-pay foundations (ICCFs) from 2010 – 2014.

Novartis is committed to doing what is right for the communities in which we operate and the many patients who depend on us. The company recently rolled out an enhanced compliance framework that empowers our people to make the right choices about the activities we undertake, ensuring that all aspects of our business meet the highest ethical standards and that we continue to meet society's high expectations. This includes an increased focus on funding responsibly, acting with clear intent, and engaging appropriately while always putting the patient first.

[View the Novartis Code of Ethics](#)

[View the full Corporate Integrity Agreement](#)

Source URL: [*https://qa1.novartis.us/esg/ethics-risk-and-compliance/corporate-integrity-agreement*](https://qa1.novartis.us/esg/ethics-risk-and-compliance/corporate-integrity-agreement)

List of links present in page

1. <https://qa1.novartis.us/esg/ethics-risk-and-compliance/corporate-integrity-agreement>
2. https://qa1.novartis.us/sites/novartis_us/files/2022-03/erc.301-v2-en-code-of-ethics_0.pdf
3. https://www.oig.hhs.gov/fraud/cia/agreements/Novartis_Corporation_06302020.pdf